Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Considering buying MRNA stock? Here's what analysts think: Moderna Inc has a consensus price target of $143.23 based on the ratings of 25 analysts. The high is $304 issued by Wolfe Research on November 9, 2021. The low is $80 issued by Deutsche Bank on August 6, 2024. The 3 most-recent analyst ratings were released by HS ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. Start slideshow: 10 Oversold Stocks You Should Know About » In trading on Tuesday, shares of Moderna entered into overs ...

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA). Shareholders who purchased shares of MRNA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moderna-loss-submission-form/?id=98139&from=3 CLASS PERIOD: January 18, 2023 to June ...

SAN DIEGO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of purchasers or acquirers of Moderna, Inc. (NASDAQ: MRNA) ("Moderna" or the "Company") securities between January 18, 2023 and June 25, 2024, inclusive (the "Class Period"), charging the Company and certain senior executives (collectively, "Defendants") with violations of the federal securities laws. Moderna investors have until October 8, 2024 to seek appointment as lead plaintiff of the Moderna class action lawsu ...

akinbostanci Introduction Moderna, Inc.'s (NASDAQ:MRNA) stock has been sluggish this past year, returning -27%. In fact, Moderna was reportedly the "most shorted S&P 500 healthcare stock in July." My last analysis focused on the company's prospects, with their COVID-19/influenza combination vaccine targeting an $8 billion-plus market. My January analysis maintained a long-term perspective, culminating in a "strong buy" recommendation, noting: The pandemic-induced revenues only scratched the surface of Moder ...

NEW YORK, Aug. 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA). Shareholders who purchased shares of MRNA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moderna-loss-submission-form/?id=97684&from=4 CLASS PERIOD: January 18, 2023 to June 25, ...

NEW YORK, Aug. 23, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 8, 2024. So what: If you purchased Moderna securities during the Class Period y ...

Key Takeaways The S&P 500 dropped 0.9% on Thursday, Aug. 22, as tech stocks faltered ahead of Fed Chair Jerome Powell's Friday remarks. Moderna shares lost ground even as the biotech firm received approval for its latest COVID-19 vaccine. Nordson shares ticked higher after the industrial machinery provider topped quarterly estimates, boosted by strength in Europe and the Asia-Pacific region. Major U.S. equities indexes fell Thursday as the Jackson Hole Economic Policy Symposium kicked off in Wyoming. Federa ...

NEW YORK, Aug. 22, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA). Shareholders who purchased shares of MRNA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moderna-loss-submission-form/?id=97059&from=4 CLASS PERIOD: January 18, 2023 to June 25, ...

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA). Shareholders who purchased shares of MRNA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moderna-loss-submission-form/?id=96723&from=3 CLASS PERIOD: January 18, 2023 to June ...